Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong by Herbert H. Loong, Carlos K. H. Wong, Linda K. S. Leung, S. C. Tan, Jason Jen, Mary Y. K. Lee, Raquel Aguiar-Ibáñez, Jingshu Wang

Get full text